All News

As I count my many blessings, my wish for you is that you are able to hold fast to the moment and breathe in all that you have, all that is dear to you now and that you, too, will fill your stockings with the presence and love of the moment. Wishing you all a very Merry Christmas!

The mental challenges of having stage 4 breast cancer are just as overwhelming as the physical ones.

Sometimes a break from routine can remind us why we're fighting to live

The PD-1 inhibitor Opdivo (nivolumab) was granted accelerated approval for patients with unresectable or metastatic melanoma following treatment with Yervoy (ipilimumab) or a BRAF inhibitor.

The mental noise that comes with cancer is deafening. Taking cancer time-outs can quiet your anxiety.

Gather together all of your ingredients and whip up something delicious just in time for the holidays.

The Food and Drug Administration approves Lynparza (olaparib) for the treatment of women with BRCA-positive advanced ovarian cancer.

Two HER2-targeting regimens anchored by Kadcyla (T-DM1) failed to outperform the standard strategy of Herceptin plus chemotherapy in women newly diagnosed with advanced HER2-positive breast cancer.

The addition of Avastin (bevacizumab) to standard neoadjuvant chemotherapy significantly improved pathologic complete response rates in women with basal-like breast cancer compared with non-basal-like subtypes.

Learning to cope with a cancer diagnosis is an ongoing process. Coming face to face with death forces one to reexamine what is really important.

The Food and Drug Administration has approved Somatuline Depot (lanreotide) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), based on findings from the phase 3 CLARINET study.

Faslodex (fulvestrant) improved overall survival by nearly six months compared with anastrozole as initial hormone therapy for postmenopausal women with estrogen receptor-positive advanced breast cancer, according to findings from the phase 2 FIRST trial.

The FDA has approved Cyramza (ramucirumab) in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer whose tumor has progressed during or following treatment with platinum-based chemotherapy.

Dr. Mary Claire King's search for the breast cancer gene spanned 20 years.

I talked about chemotherapy and the kindness of nurses who helped me to make those early days of the treatment chair easier: the value of listening, the importance of a smile or touch, the validation of my fears and hopes.

Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54 percent when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.

There is comfort in having a simple cause and effect. The unknown can be difficult to accept.

Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.

Karen Durham never expected to be speaking on behalf of the Metastatic Breast Cancer Alliance

The PD-1 inhibitor Keytruda (pembrolizumab) has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer (TNBC).

When 34-year-old Jen Levinson was diagnosed with stage 2 breast cancer in 2000, the breast cancer world gained a powerful advocate -- but it wasn't Jen, it was her mother.

Abraxane (nab-paclitaxel) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk, early breast cancer, according to results presented at the 2014 San Antonio Breast Cancer Symposium.

The addition of the investigational PI3K inhibitor pictilisib to the aromatase inhibitor Faslodex in patients with metastatic breast cancer yielded some intriguing findings in the FERGI study.

Research presented at the 2014 San Antonio Breast Cancer Symposium shows that high levels of lymphocytes, white blood cells found in the immune system, could help identify women with HER2-positive breast cancer who could forego chemotherapy.

I had forgotten how much I learn during the week of SABCS from oncologists while waiting for the shuttle

Researchers gathered at the annual meeting of the American Society of Hematology to learn about survivorship issues and the late effects their patients encounter years, even decades, after therapy.

Andrea Ivory had an epiphany shortly after being diagnosed with breast cancer in 2004 at age 45.

We all asked why we got breast cancer. Now you can help answer the question.

Three little words that are no less terrifying the second time around.

Treatment with the experimental agent elotuzumab in combination with Revlimid and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma in a phase 1b/2 study.